Refractory Hodgkin lymphoma: time for targeted therapies?

Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma

Targeted immunotherapy in Hodgkin lymphoma.

In this issue of Blood, Rothe et al introduce a new principle of targeted Hodgkin lymphoma (HL) immunotherapy in their report from a phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13.

Treatment of relapsed/refractory Hodgkin lymphoma.

Novel targeted therapies for mantle cell lymphoma

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by short median survival despite intensive therapies. The clinical behavior of MCL may be due to the complex pathophysiology of the disease which includes its genetic hallmark, the chromosomal translocation t(11;14) resulting in aberrant expression of cyclin D1, alteration in the DNA damage response, and constitutive ac...

Hodgkin Lymphoma and Anaplastic Variants of Non-Hodgkin Lymphoma

  Background and Objectives: Classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) and some cases of diffuse large B cell lymphoma (DLBCL) have overlapping morphologic features. Since they all represent distinct clinico-pathologic entities, we explored the differential diagnostic impact of immunophenotyping to discriminate between them. Materials and Methods:...